Bruker Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Bruker şirketinin kazançları yıllık ortalama -22.1% oranında azalırken, Life Sciences sektörünün kazançları yıllık 3.8% oranında azalan oldu. Gelirler yıllık ortalama 10.1% oranında artan oldu.
Anahtar bilgiler
-22.06%
Kazanç büyüme oranı
-21.46%
EPS büyüme oranı
| Life Sciences Sektör Büyümesi | 21.51% |
| Gelir büyüme oranı | 10.12% |
| Özkaynak getirisi | -0.38% |
| Net Marj | -1.05% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • May 14
BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds
Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.
Anlatı Güncellemesi • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.Anlatı Güncellemesi • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.Anlatı Güncellemesi • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Seeking Alpha • Mar 31
Bruker: A Better, Yet Speculative Proposition
Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking AlphaAnlatı Güncellemesi • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.Anlatı Güncellemesi • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.Anlatı Güncellemesi • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.Analiz Makalesi • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...Anlatı Güncellemesi • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.Anlatı Güncellemesi • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.Anlatı Güncellemesi • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.Anlatı Güncellemesi • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.Anlatı Güncellemesi • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.Analiz Makalesi • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...Anlatı Güncellemesi • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.Anlatı Güncellemesi • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.Analiz Makalesi • Aug 10
Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge
NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...Anlatı Güncellemesi • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).Analiz Makalesi • Jun 25
Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price
Bruker Corporation's ( NASDAQ:BRKR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now...Analiz Makalesi • May 31
A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Key Insights The projected fair value for Bruker is US$43.42 based on 2 Stage Free Cash Flow to Equity Bruker's...Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Bruker nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 3,459 | -36 | 960 | 399 |
| 31 Dec 25 | 3,437 | -22 | 944 | 395 |
| 30 Sep 25 | 3,439 | -24 | 946 | 400 |
| 30 Jun 25 | 3,443 | 80 | 933 | 400 |
| 31 Mar 25 | 3,446 | 80 | 923 | 392 |
| 31 Dec 24 | 3,366 | 113 | 893 | 377 |
| 30 Sep 24 | 3,241 | 305 | 853 | 356 |
| 30 Jun 24 | 3,120 | 352 | 802 | 329 |
| 31 Mar 24 | 3,001 | 402 | 763 | 308 |
| 31 Dec 23 | 2,965 | 427 | 730 | 295 |
| 30 Sep 23 | 2,818 | 319 | 687 | 275 |
| 30 Jun 23 | 2,715 | 319 | 644 | 260 |
| 31 Mar 23 | 2,621 | 312 | 625 | 248 |
| 31 Dec 22 | 2,531 | 297 | 608 | 236 |
| 30 Sep 22 | 2,506 | 275 | 598 | 231 |
| 30 Jun 22 | 2,476 | 274 | 605 | 226 |
| 31 Mar 22 | 2,458 | 282 | 577 | 223 |
| 31 Dec 21 | 2,418 | 277 | 563 | 221 |
| 30 Sep 21 | 2,362 | 270 | 544 | 220 |
| 30 Jun 21 | 2,264 | 238 | 518 | 216 |
| 31 Mar 21 | 2,118 | 204 | 485 | 204 |
| 31 Dec 20 | 1,988 | 158 | 472 | 198 |
| 30 Sep 20 | 1,960 | 158 | 470 | 188 |
| 30 Jun 20 | 1,970 | 165 | 480 | 185 |
| 31 Mar 20 | 2,035 | 177 | 503 | 190 |
| 31 Dec 19 | 2,073 | 197 | 500 | 188 |
| 30 Sep 19 | 2,026 | 207 | 491 | 186 |
| 30 Jun 19 | 1,972 | 189 | 473 | 182 |
| 31 Mar 19 | 1,925 | 184 | 459 | 177 |
| 31 Dec 18 | 1,896 | 180 | 449 | 173 |
| 30 Sep 18 | 1,873 | 98 | 443 | 172 |
| 30 Jun 18 | 1,842 | 92 | 440 | 171 |
| 31 Mar 18 | 1,813 | 84 | 432 | 167 |
| 31 Dec 17 | 1,766 | 79 | 420 | 162 |
| 30 Sep 17 | 1,706 | 151 | 407 | 157 |
| 30 Jun 17 | 1,664 | 161 | 399 | 154 |
| 31 Mar 17 | 1,621 | 152 | 396 | 151 |
| 31 Dec 16 | 1,611 | 154 | 394 | 148 |
| 30 Sep 16 | 1,619 | 146 | 393 | 148 |
| 30 Jun 16 | 1,621 | 111 | 393 | 144 |
| 31 Mar 16 | 1,646 | 119 | 390 | 145 |
| 31 Dec 15 | 1,624 | 102 | 392 | 146 |
| 30 Sep 15 | 1,654 | 66 | 408 | 151 |
| 30 Jun 15 | 1,677 | 60 | 420 | 158 |
Kaliteli Kazançlar: BRKR şu anda kârlı değil.
Büyüyen Kar Marjı: BRKR şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: BRKR kârlı değildir ve zararlar son 5 yılda yılda 22.1% oranında artmıştır.
Büyüme Hızlandırma: BRKR 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: BRKR kârlı olmadığından, geçmiş yıl kazanç büyümesinin Life Sciences sektörüyle ( 3.8% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: BRKR hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -0.38% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/20 15:29 |
| Gün Sonu Hisse Fiyatı | 2026/05/20 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bruker Corporation 29 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |